



## COMPANY OVERVIEW

Cardax is a life sciences company that devotes substantially all of its efforts to developing safe anti-inflammatory dietary supplements and drugs. Cardax is initially focusing on astaxanthin, which is a powerful and safe naturally occurring anti-inflammatory without the side effects of currently marketed anti-inflammatories. The safety and efficacy of Cardax's products have not been directly evaluated in clinical trials or confirmed by the FDA.

## RECENT NEWS

### **Cardax and GNC Announce Expanded ZanthoSyn® Sales and Marketing Program**

Dec 3 2018, 8:00 AM EST

### **Cardax Names Former Amarin Head of Development Paresh N. Soni, MD, PhD, to lead Clinical and Regulatory Strategy**

Nov 28 2018, 5:00 PM EST

## STOCK OVERVIEW

Symbol	CDXI
Exchange	OTCQB
Market Cap	26.58m
Last Price	\$0.20
52-Week Range	\$0.13 - \$0.44

12/10/2018 03:40 PM EST

## INVESTOR RELATIONS

Cardax, Inc.  
T: (808) 457-1400  
[investors@cardaxpharma.com](mailto:investors@cardaxpharma.com)

## MANAGEMENT TEAM

**David G. Watumull**  
President and CEO, Director

**Gilbert M. Rishton, Ph.D.**  
Chief Science Officer

**John B. Russell**  
Chief Financial Officer

**David M. Watumull**  
Chief Operating Officer

**Timothy J. King, Ph.D.**  
Vice President, Research

## CARDAX, INC.

2800 Woodlawn Drive  
Suite 129  
Honolulu, HI 96822

## DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.